Eikon Therapeutics, Inc. (EIKN)
Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
9. 77
-0.18
-1.809%
$
29.36M Market Cap
- P/E Ratio
- Div Yield
181,200 Volume
- Eps
$ 9.95
Previous Close 
Want to track EIKN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating
Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a robust oncology-focused pipeline. EIKN's ASCO data for EIK1001 in NSCLC showed a 63.1% ORR and favorable safety, but the market response was muted. Cash reserves of $596m provide a runway into 2027 despite high R&D burn; valuation is now below cash, reflecting skepticism.
Seekingalpha | 1 month ago
